- Svelte Medical has launched its SLENDER Sirolimus-Eluting Coronary Stent-On-A-Wire Integrated Delivery System in Europe
- The firm says, the SLENDER IDS is the narrowest drug eluting stent on the market
- It is designed to reduce the catheter size and steps necessary to perform percutaneous coronary intervention
- “SLENDER IDS will result in a paradigm shift in interventional cardiology,” Dr. Ferdinand Kiemeneij
- “Downsizing is the future of interventional cardiology, and SLENDER IDS is the first ultra-low profile DES,” Dr. Giovanni Amoroso
Svelte Medical, a medical technology headquartered in New Providence, New Jersey, has launched its SLENDER Sirolimus-Eluting Coronary Stent-On-A-Wire Integrated Delivery System (IDS) in Europe.
According to the firm, the SLENDER IDS is the narrowest drug eluting stent (DES) on the market. It is designed to reduce the catheter size and steps necessary to perform percutaneous coronary intervention (PCI) – a non-surgical procedure used to treat the stenotic coronary arteries of the heart.
Dr. Ferdinand Kiemeneij, who treated the first patient with the CE Mark certified SLENDER IDS at Tergooi Hospital in Blaricum, said, “SLENDER IDS will result in a paradigm shift in interventional cardiology. SLENDER IDS is a platform designed to improve patient care by breaking with current interventional standards, and I am proud to be involved with this project.”
“Downsizing is the future of interventional cardiology, and SLENDER IDS is the first ultra-low profile DES. The ability to reduce catheter size without compromise to performance minimizes vascular trauma and enables use of the transradial approach, with all of its well-known clinical benefits, across broader subsets of patients. This makes for a much more pleasant patient experience,” said Dr. Giovanni Amoroso, a practicing interventional cardiologist at OLVG Hospital in Amsterdam, The Netherlands.
By combining the latest guide wire, delivery balloon, stent and drug coating technologies into a single ‘all-in-one’ fixed-wire system, SLENDER IDS attains low profiles and performance, unlike any other DES.
Asahi ACT ONE wire technology provides perfect steering while proprietary Balloon Control Band (BCB) technology permits controlled balloon growth to safely conduct direct stenting and high-pressure post-dilatation(s).
DISCREET drug coating, applied to a highly conformable cobalt chrome stent, is composed of the well-studied drug sirolimus and a natural, amino acid-based polyesteramide bioresorbable drug carrier proprietary to DSM Biomedical. In the clinical studies, exceptionally low TLR was observed while no deaths or stent thromboses were reported beyond three years.
Visit the product page: SLENDER IDS Integrated Delivery System